[1st successful immunization of pancreas and colorectal carcinoma patients with CO17-1A-vaccine].
The baculovirus-derived extracellular domain of the CO17-1A antigen induced cellular and/or humoral immune responses in curatively resected colorectal and pancreatic cancer patients after at least three applications of the vaccine. The vaccine application was safe and non-toxic. The clinical efficacy of the vaccine needs to be evaluated in larger, randomized clinical trials.
D000368:Aged; D000912:Antibodies, Neoplasm / Q000097:blood; D000951:Antigens, Neoplasm / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology / Q000627:therapeutic use*; D015815:Cell Adhesion Molecules / Q000276:immunology*; D015179:Colorectal Neoplasms / Q000276:immunology* / Q000601:surgery; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D000071858:Epithelial Cell Adhesion Molecule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000276:immunology* / Q000601:surgery; D019444:Vaccines, DNA / Q000276:immunology / Q000627:therapeutic use*
D000912:Antibodies, Neoplasm; D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D015815:Cell Adhesion Molecules; D000071858:Epithelial Cell Adhesion Molecule; D019444:Vaccines, DNA; C050928:carcinoma-associated antigen 17-1A